JAAD online
Vasculitis and panniculitis associated with vemurafenib

https://doi.org/10.1016/j.jaad.2012.05.019Get rights and content

References (5)

  • P.B. Chapman et al.

    Improved survival with vemurafenib in melanoma with BRAF V600E mutation

    N Engl J Med

    (2011)
  • Justice RL. Center for Drug Evaluation and Research. Application number: 202429Orig1s000. Summary review. Available...
There are more references available in the full text version of this article.

Cited by (23)

  • Immune-related adverse events of cancer immunotherapies targeting kinases

    2022, Pharmacology and Therapeutics
    Citation Excerpt :

    Bullous eruptions have been reported mostly with sorafenib, lichen with imatinib, vitiligo with vemurafenib and alopecia with erlotinib/gefitinib. Several cases of leukocytoclastic vasculitis (Guillemois et al., 2018; Mirouse et al., 2016; Mössner et al., 2015; Novoa et al., 2012; Ueno et al., 2017) and subacute or discoid cutaneous lupus (Calabrese et al., 2020; Freedman et al., 2020; Pinard, Patel, Granter, Vleugels, & Merola, 2018; Russell-Goldman & Nazarian, 2020) are also reported. Renal toxicity related to KIs has mainly been reported in patients with renal cell and thyroid malignancies, including raised creatinine, proteinuria/nephrotic syndrome, hematuria and renal failure (Mielczarek et al., 2021; Nervo et al., 2021).

  • Tolerability of BRAF/MEK inhibitor combinations: Adverse event evaluation and management

    2019, ESMO Open
    Citation Excerpt :

    Myalgia is another very common AE, occurring with BRAFi+MEKi in 14%–19% (table 2); frequencies are similar for the different BRAFi (figure 2). Vasculitis is mainly described in single patients treated with BRAFi as cutaneous side effects in the context of panniculitis,45 50–53 and as leukocytoclastic vasculitis,45 54 but also involving the kidney as glomerulonephritis55 56 and the eye as retinal vasculitis.57 For treatment of mild symptoms of arthralgia or myalgia, NSAIDs or low-dose corticosteroids can be applied.

  • Delayed-onset vemurafenib-induced panniculitis

    2017, JAAD Case Reports
    Citation Excerpt :

    Cutaneous side effects are common with BRAF-targeted therapies; however, panniculitis is an unusual reaction. Acute vemurafenib induced panniculitis has been biopsy confirmed and reported in 22 melanoma patients whose presentations ranged from 3 days to 111 days (mean, 30.6 days; median, 15 days).3-8 A single reported pediatric patient treated for a brainstem glioma with vemurafenib had delayed-onset neutrophilic panniculitis after 10 months of therapy.9

  • Scurvy in a patient on vemurafenib

    2015, JAAD Case Reports
    Citation Excerpt :

    Within 1 month, the patient had recurrence in the right axilla and brain; he died from his disease 8 months after the diagnosis of scurvy. Cutaneous side effects associated with vemurafenib include photosensitivity, alopecia, xerosis, papillomas, squamous cell carcinomas, panniculitis, keratosis pilaris–like eruptions, facial erythema, palmar-plantar hyperkeratosis, and acneiform eruptions.1-4 Dysgeusia and decreased appetite are common side effects, reported in 13% and 18.8%, respectively, of 468 patients combined from the phase II and phase III trials.5

  • Vemurafenib-induced toxic epidermal necrolysis

    2014, Annales de Dermatologie et de Venereologie
View all citing articles on Scopus

Funding sources: Dr Gerstenblith received grants from the Char and Chuck Fowler Family Foundation and the Skin Cancer Foundation Melissa K. Bambino Memorial Award.

Disclosure: Dr Koon has served on the advisory board and speaker’s bureau for Genentech. Dr Gerstenblith received grants from the Char and Chuck Fowler Family Foundation and the Skin Cancer Foundation Melissa K. Bambino Memorial Award. Drs Novoa and Honda have no conflicts of interest to declare.

View full text